A global Phase 2b study evaluating GSBR-1290 in type 2 diabetes patients
Latest Information Update: 22 Dec 2023
At a glance
- Drugs Aleniglipron (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
Most Recent Events
- 18 Dec 2023 According to a Structure Therapeutics media release, Phase 2 study in T2DM is planned for the second half of 2024 to optimize the efficacy and tolerability of GSBR-1290 in this patient population.
- 29 Sep 2023 According to a Structure Therapeutics media release, this study is expected to include approximately 500 individuals across the United States, Europe and Japan.
- 02 Jun 2023 New trial record